BlueOwl

Blue Owl's 15min Chart Shows MACD Death Cross, KDJ Death Cross.

Blue Owl: Oppenheimer maintains Outperform, PT down to $24 from $27.

Blue Owl Capital

Blue Owl

AI Fears Impact Private Credit, Blue Owl Slumps 26% Amid Tech Rout

Blue Owl shares rise 5.89% intraday after announcing 7.8% dividend yield and $307B AUM growth.

GE HealthCare

GE HealthCare: Barclays Raises PT to $87, Maintains Equal-Weight Rating

Catalyst<ul> <li>Most analysts rate OWL Buy or Strong Buy, showing broad institutional optimism.</li> <li>Net inflow trends among medium large and extra-large orders suggest increased institutional confidence in OWL.</li></ul>Risk<ul> <li>Bearish signals are obviously dominant in recent technical indicators (3 bearish vs 1 bullish), indicating increased downside pressure.</li> <li>Technical indicators show that the market is in a volatile state and the direction is not clear enough, which may lead to increased uncertainty for investors.</li></ul>

Key Factors

Blue Owl Capital (OWL) reported fiscal 2025 Q4 earnings on Feb 5, 2026, surpassing revenue and earnings estimates while reaffirming 2026 guidance.Blue Owl Capital (OWL) announced a $0.225/share quarterly dividend and crossed $307 billion in assets under management (AUM) in Q4 2025.Blue Owl Capital (OWL) shares surged 6.12% premarket after exceeding Q4 2025 earnings estimates and crossing $300 billion AUM, with co-CEOs dismissing AI-driven selloff risks.Blue Owl Capital (OWL) aims for a 58.5% fee-related earnings (FRE) margin in 2026, reporting $56 billion in 2025 capital commitments and expanding digital infrastructure and alternative credit platforms.Blue Owl Capital (OWL) shares fell 6.72% intraday amid surging software industry bad debt to $46.9B and intensifying AI-driven private credit market risks.

Recent Updates

OWL News